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Abstract
The role of genetics in the causation of cerebral palsy has become the focus of
many studies aiming to unravel the heterogeneous etiology behind this frequent
neurodevelopmental disorder. A recent paper reported two unrelated children
with a clinical diagnosis of cerebral palsy, who carried the same de novo
c.1000G > A (p.Asp334Asn) variant in FBXO31, encoding a widely studied
tumor suppressor not previously implicated in monogenic disease. We now
identified a third individual with the recurrent FBXO31 de novo missense variant, featuring a spastic-dystonic phenotype. Our data confirm a link between
variant FBXO31 and an autosomal dominant neurodevelopmental disorder
characterized by prominent motor dysfunction.
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Recurrent FBXO31 Variant in Cerebral Palsy

Introduction
Cerebral palsy (CP) represents a major neurodevelopmental disorder (NDD) with an estimated prevalence of 2-3
per 1000 live births.1,2 The clinical presentation is heterogeneous and the defining features comprise disorders of
movement and posture, usually described as non-progressive, but prone to change throughout the course of disease.3 The motor disorder arises in early infancy and
persist until the end of life, often accompanied by additional features such as developmental delay, intellectual
disability (ID), and speech impairment.3 The etiologic
implication of environmental factors has been investigated
extensively, whereas genetic contributions to CP have only
begun to be elucidated.4
Two recent large-scale whole-exome sequencing (WES)
studies described patients with CP who harbored causative
variants in known NDD-associated genes as well as in
genes not previously linked to human Mendelian disorders.5,6 Jin and colleagues5 identified two unrelated CP-affected individuals with an identical de novo missense
variant (c.1000G > A, p. Asp334Asn) in FBXO31, encoding F-box only protein 31 (FBXO31), a molecule for
which a relationship to disease had only been known from
cancer research.7 The features shared by both subjects
included spasticity, ID, speech deficits, and behavioral
abnormalities.5 Herein, we report on the identification of
the recurrent FBXO31 c.1000G > A (p. Asp334Asn) variant in a patient with a complex movement-disorder syndrome, providing the first independent replication of the
involvement of a specific de novo FBXO31 mutation in a
human NDD. Additionally, we present a comparison
of phenotype abnormalities observed in all three FBX
O31-mutated individuals, contributing information for a
better understanding of this newly identified monogenic
condition.

Methods
The proband presented here was identified as part of a
cohort of ~950 whole-exome-sequenced individuals with
various types of dystonic disorders. Clinical evaluation
was performed at the Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovakia. Prior to the
collection of clinical information and data from genomic
testing, written informed consent was obtained from the
proband‘s legal representatives (parents). The case study
was carried out in accordance with the Declaration of
Helsinki and under protocols approved by respective ethical committees. For the family trio, WES was conducted
at the sequencing core of Helmholtz Center Munich using
previously published methods.6 Briefly, exome capture was
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performed using Agilent SureSelect v6 reagents and exome
libraries were subjected to paired-end sequencing on an
Illumina HiSeq4000. Sequence-data processing was done
with a validated in-house pipeline, implementing Burrows-Wheeler-Aligner, SAMtools, ExomeDepth, and custom scripts. An average of 96-fold to 114-fold coverage
was obtained for the three exomes, with 97%–98% of the
target nucleotides covered ≥20-fold. Variants were annotated with gene, transcript, functional class, population
frequency, deleteriousness predictions, and ClinVar entry.
The proband‘s entire WES data set was searched for
pathogenic or likely pathogenic variants8 in reported disorder-associated genes, as described.6 For the identification of de novo alleles, variants were called in all three
samples simultaneously, and de novo events were detected
by bioinformatics subtraction analysis.6,9

Results
Case presentation
We report the case of a 9-year-old boy demonstrating a
complex, non-progressive movement-disorder syndrome
dominated by spasticity and dystonia (Table 1). The proband was born at term per caesarian section after an
uneventful pregnancy. He was the first child of unrelated,
healthy parents of Slovakian descent. Family history was
unremarkable. There were no postpartum complications
and no congenital anomalies. During the first months of
life, he presented with muscular hypotonia and delayed
acquisition of developmental milestones. He rolled over at
the age of 6 months, but did not come to sit until
9 months. He walked with support at 20 months. He spoke
in single words at the age of 12 months, but lost the ability
to speak at 18 months. Neuropediatric assessment at the
age of 2 years documented a conversion to limb spasticity
from hypotonia, more pronounced in the lower extremities.
In addition, involuntary abnormal twisting and postural
abnormalities affecting all four limbs and occasionally the
trunk were noted. A working clinical diagnosis of spasticdystonic CP was established. Over the following 7 years,
there was no significant worsening of tone and movement
abnormalities, but the proband required assistance with
activities of daily living due to severe physical disability. He
could not walk longer distances without bilateral support
and he displayed reduced manual dexterity. He was able to
follow two-step commands, but had no expressive language.
Examined elsewhere, he was diagnosed with an intellectual
disability. Because of his motor and speech impairments, he
has never been able to engage in active play with his peers.
At the latest neurological evaluation (age 9 years), he was
alert, interactive with eye contact, but he did not vocalize or
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Figure 1. A recurrent FBXO31 missense variant in patients with neurodevelopmental disease and movement disorder. (A) Linear model of
FBXO31 and schematic representation of the cellular role of FBXO31 in SCF (SKP1, cullin, F-box protein) complex-mediated regulation of cyclin D1
abundance. The location of the patient-specific recurrent missense variant at amino acid position 334 is indicated. * the previously described cases
are labeled as in Jin et al.5 (B) Three-dimensional model of the FBXO31-SKP1-cyclin D1 complex (PDB: 5VZU). The spatial proximity of the mutated
Asp334 residue (stick-and-ball representation) to FBXO31‘s substrate cyclin D1 (stick representation) is illustrated.

verbalize. He had generalized dystonia involving his arms,
legs, and trunk, as well as signs of pyramidal tract dysfunction including spasticity (more severely affecting the legs
than the arms), hyperreflexia, and clonus in both legs.
Mobility was impaired, with an unsteady spastic-dystonic
gait. His intellectual development was estimated as moderately compromised, although formal IQ testing had not
been performed. No distinctive craniofacial features or
physical defects were documented.

Diagnostic evaluations
Routine laboratory tests were non-diagnostic, although
slightly elevated levels of lactate in blood and urine were
documented once. A series of metabolic studies were
unrevealing. On brain MRI (age 3 years), there was
reduced white-matter volume in the parietal and occipital
lobes bilaterally, along with an aspect of global whitematter dysmyelination. After targeted molecular investigations had failed to provide an etiologic diagnosis, the proband and his parents underwent trio-WES in a research
context. The analysis revealed that the proband was
heterozygous for a FBXO31 c.1000G > A (p. Asp334Asn)
missense substitution, which had occurred de novo. This
variant, absent from control databases (gnomAD, inhouse exomes), has been described recently in two individuals with an NDD diagnosed as spastic diplegic CP.5
The variant affected a conserved residue10 within a

functionally important domain of the encoded protein,
involved in the interaction with FBXO31‘s substrate
cyclin-D1 (Fig. 1A and B).5,11 According to the guidelines
of the American-College-of-Medical-Genetics-and-Genomics,8 the variant was classified as “pathogenic”. No other
potentially disease-relevant variants were observed in the
proband‘s WES data.

Comparative phenotypic analysis
A clinical overview of the proband presented here and the
individuals reported by Jin et al.5 is given in Table 1. The
three cases shared a presentation of motor and/or speech
delay, and all had ID that varied from mild to moderate.
Additional consistent features included profound abnormalities of speech and muscle tone. The latter comprised
spasticity (as seen in all three patients), predominantly
affecting the lower limbs and leading to a diagnosis of CP
in each subject,5 as well as dystonia (observed in the herein
reported case). Other neurological and non-neurological
manifestations such as congenital malformations, behavioral issues, minor dysmorphia, and neuroanatomical alterations occurred in two or only one of the subjects.

Discussion
FBXO31 encodes a 539 amino-acid protein containing an
N-terminal F-box domain and a C-terminal substrate-

ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association

953

Recurrent FBXO31 Variant in Cerebral Palsy

I. Dzinovic et al.

Table 1. FBXO31-related disease - Genetic findings and clinical features of the present proband and two cases reported by Jin et al.5
F2181

Present proband

F6991

Age at last assessment
Gender
Genomic variant (GRCh37/hg19)
FBXO31 cDNA change
(NM_024735.5)
FBXO31 protein change
(NP_079011.3)
Zygosity
Inheritance
Family history
Prenatal findings

9 years
Male
Chr16:87367889C > T
c.1000G > A

9 years
Female
Chr16:87367889C > T
c.1000G > A

10 years
Male
Chr16:87367889C > T
c.1000G > A

p. Asp334Asn

p. Asp334Asn

p. Asp334Asn

Heterozygous
de novo
Negative
No

Heterozygous
de novo
Negative
No

Gestational age at birth (weeks)
Malformations at birth

In term (38)
No

Developmental delay
Hypotonia
Intellectual disability
Speech impairment

Yes (global)
Yes (neonatal)
Yes (moderate)
Loss of speech at the age of
1.5 years, receptive language
disorder
No

In term (40)
Cleft palate, intestinal malrotation,
and midgut volvulus requiring small
bowel resection
Yes (global)
Yes (neonatal)
Yes (mild)
Dysarthria, mixed
receptive/expressive language
disorder
Attention deficit hyperactivity
disorder
Lower-limb spasticity

Heterozygous
de novo
Negative
Decreased fetal movements,
mild intrauterine growth
restriction
In term (N/A)
No

Behavioral abnormalities
Movement disorder
Diagnosis of cerebral palsy (CP)
Loss of independent ambulation
Brain magnetic resonance imaging

Dysmorphic signs

Generalized dystonia, limb spasticity
(lower limbs > upper limbs)
Yes (spastic-dystonic CP)
No
Bilateral occipital and parietal whitematter volume reduction, irregular
white-matter dysmyelination
No

Yes (global)
Yes (neonatal)
Yes (moderate)
Speech not fully acquired,
receptive language disorder
Attention deficit hyperactivity
disorder
Lower-limb spasticity

Yes (spastic diplegic CP)
No
Normal

Yes (spastic diplegic CP)
No
Mild ventricular dilatation, thin
corpus callosum

Esotropia

Strabismus

N/A, not available.
Labeled as in Jin et al.5

1

recognition domain (Fig. 1A).11 FBXO31 is a component
of a SKP1-cullin-F-box (SCF)-type ubiquitin ligase, a
ubiquitously expressed complex involved in proteasomedependent degradation of various regulatory proteins
such as cyclin-D1 (Fig. 1A and B).11,12 Deregulation of
SCF complexes and their subunits has been linked to
diverse human pathologies including monogenic disorders.13 For instance, within the class of FBXO (F-boxonly) proteins, FBXO11 has been associated with an autosomal dominant NDD (MIM:618089).14 Moreover, biallelic variants in FBXO7 cause Parkinson’s disease-15
(MIM:260300),15,16 linking the occurrence of movement
disorder symptoms to FBXO gene perturbation.
A disease-relevant role of FBXO31 has been initially
studied in the context of oncogenesis, where the protein
was postulated to act as a potent tumor suppressor.7 More
recent research suggests that FBXO31 is also indispensable
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for the normal function of the nervous system, impacting
neural network formation and synaptic strength.17
Although the mechanistic basis for how mutation of
FBXO31 leads to an NDD remains an area of investigation,
Jin et al.5 have shown that c.1000G > A (p. Asp334Asn)
produced decreased levels of FBXO31‘s substrate cyclin-D1
in patient-derived cells, consistent with a gain-of-function
effect. We have now identified a third individual with the
c.1000G > A (p. Asp334Asn) variant, displaying phenotype
characteristics closely resembling those of the originally
described cases.5 Emerging hallmarks of FBXO31-related
disease seem to include a delay in psychomotor development, dysfunction of both pyramidal and extrapyramidal
systems (as evidenced by the manifestation of spasticity and
dystonia), impairments in expressive and receptive language, and ID. Notably, a diagnostic label of CP had been
given to all three FBXO31-mutated individuals. This
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finding supports the recent idea that monogenic defects
represent important contributors to the pathogenesis of CP
and CP-like syndromes.5,6 The proportion of patients diagnosed with CP whose conditions are attributable to
FBXO31 variants remains to be determined. In addition,
further studies are required to clarify whether monoallelic
FBXO31 variants other than c.1000G > A (p. Asp334Asn)
are disease-causing.
Collectively, this report confirms that a recurrent missense
variant in FBXO31 causes a novel neurodevelopmental syndrome. The occurrence of de novo FBXO31 mutation should
be considered in patients with CP and spastic-dystonic disorders for which no alternative cause is found.
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